Evidence map›Paper›PMID 30408609›Full record

ReviewMethods (San Diego, Calif.)2019

Determining degradation intermediates and the pathway of 3' to 5' degradation of histone mRNA using high-throughput sequencing.

Christopher E Holmquist, William F Marzluff

Abstract readReview
In one paragraph

Review in Methods (San Diego, Calif.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Measuring the tail: Methods for poly(A) tail profiling.Wiley interdisciplinary reviews. RNA · 2023
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Christopher E HolmquistDepartment of Chemical Biology and Medicinal Chemistry, University of North Carolina, Chapel Hill, NC 27599, United States.
William F MarzluffDepartment of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC 27599, United States. Electronic address: marzluff@med.unc.edu.

Funding

CONTROL OF HISTONE MRNA SYNTHESISR01GM029832 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DOMINSKI, ZBIGNIEW, MARZLUFF, WILLIAM F. · 1985 to 2022
$9.0M
NIGMS NIH HHS R01 GM029832
6 · The paper itself

Abstract

The half-life of an mRNA is an important parameter contributing to the steady-state level of the mRNA. Rapid changes in mRNA levels can result from decreasing the half-life of an mRNA. Establishing the detailed pathway of mRNA degradation for a particular class of mRNAs requires the ability to isolate mRNA degradation intermediates. High-throughput sequencing provides a method for detecting these intermediates. Here we describe a method for determining the intermediates in 3' to 5' degradation. Characterizing these intermediates requires not only determining the precise 3' end of the molecule to a single nucleotide resolution, but also the ability to detect and characterize any untemplated nucleotides present on the intermediates. We achieve this by ligating a known sequence to all the 3' termini in the cell, and then sequence the 3' termini and the ligated linker to identify any alterations to the genomic reference sequence. We have applied this method to characterize the intermediates in histone mRNA metabolism, allowing us to deduce the pathway of 3' to 5' degradation. This method can potentially be applied to any RNA, and we discuss possible strategies for extending the method to include simultaneous determination of the 3' and 5' end of the same RNA molecule.

Indexed as

Adenosine MonophosphateBase PairingBase SequenceCell CycleCell LineDNA, ComplementaryGene LibraryHalf-LifeHigh-Throughput Nucleotide SequencingHistonesHumansImidazolesmRNA Cleavage and Polyadenylation FactorsNuclear ProteinsNucleic Acid ConformationOligoribonucleotidesadenosine 5'-phosphorimidazolideAdenosine MonophosphateDNA, ComplementaryHistonesImidazolesmRNA Cleavage and Polyadenylation FactorsNuclear ProteinsOligoribonucleotidesRNARNA, MessengerRNA primersSLBP protein, human

Identifiers

PMID30408609
PMCPMC7252413

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.